Saddle Up for Innovation with Agilent
-
Join Agilent at Booth 601 in San Antonio to explore innovations designed to help histology laboratories improve efficiency, visibility and decision-making.
Connect with Agilent experts and:
- See live demonstrations of the Dako Omnis Family, S540MD Slide Scanner System
and Magnis NGS Prep System
- Learn how the Pathfinder Program uses specimen tracking and laboratory data to
identify workflow bottlenecks and support faster, more informed decisions
- Attend engaging booth presentations featuring the latest innovations and
perspectives from Agilent
- Network with members of the histology community at our
Histology Kickoff on Friday, September 25, at 7:00 PM.
Press Releases
Agilent Completes Acquisition of Biocare Medical
Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP. Following the close of the transaction, Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group.
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
Agilent announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
Agilent announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.
Ask a Question
To request more information about the conference content or learn more about Agilent solutions contact:
Agilent Public Relations
pdl-business-pr@agilent.com